Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002 that completed phase I/II clinical trial in subjects with DMD; phase I clinical trial for treating heart failure; and phase I/II clinical trial in subjects with myocardial infarction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Prior to a reverse merger in 2013 with Nile Therapeutics, Capricor Therapeutics, Inc. was known as Capricor, Inc. With the latter not ever itself SBIR involved, the firm want public in Feb 2007 -- also through a reverse merger with SMII, a shell company involved in internet mergers. The Nile-Capicor blended entity focused on the discovery and development of cardiac stem cell therapeutics to support or replace cells that have been damaged or lost due to chronic and acute heart disease
